PT - JOURNAL ARTICLE AU - Vidya Menon AU - Masood A Shariff AU - Victor Perez Gutierrez AU - Juan M Carreño AU - Bo Yu AU - Muzamil Jawed AU - Marcia Gossai AU - Elisenda Valdez AU - Anjana Pillai AU - Usha Venugopal AU - Moiz Kasubhai AU - Vihren Dimitrov AU - Florian Krammer TI - High Initial Titres of Anti-Spike Antibodies following SARS-CoV-2 Infection is Associated with Faster Decay Rates at Four Months Follow-Up AID - 10.1101/2021.03.02.21252362 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.02.21252362 4099 - http://medrxiv.org/content/early/2021/03/02/2021.03.02.21252362.short 4100 - http://medrxiv.org/content/early/2021/03/02/2021.03.02.21252362.full AB - Background Dynamics of humoral immune responses to SARS-CoV-2 antigens following infection suggests an initial decay of antibody followed by subsequent stabilization. We aim to understand the longitudinal humoral responses to SARS-CoV-2 nucleocapsid (N) protein and spike (S) protein and to evaluate their correlation to clinical symptoms among healthcare workers (HCW).Methods In this cross-sectional longitudinal cohort study done in two phases over four months, HCW underwent serial qualitative serology testing for anti-N antibody, quantitative MSH-ELISA to detect Receptor Binding Domain and full-length S reactive antibodies and completed online surveys about COVID-19 related symptoms and healthcare/community exposure.Results Anti-N antibody positivity was 27% and anti-S positivity was 28% in Phase 1. In Phase 2 anti-S titres were higher in symptomatic than in asymptomatic positive subjects in Phase 1. Marginally higher titers were seen in asymptomatic compared to the symptomatic positive subgroup in Phase 2. A positive correlation was noted between age, number and duration of symptoms, and Phase 1 anti-S antibody titre. A strong correlation was observed between Phase 1 titers and decay of anti-S antibody titres between the two phases. Significant correlation with rate of decay was also noted with fever, GI symptoms, and total number and duration of COVID-19 symptoms.Conclusions Higher initial anti-S antibody titres were associated with larger number and longer duration of symptoms as well as faster decay during the two time points.Question What is the decay rate of neutralizing antibodies among SARS-CoV-2 infected healthcare workers?Findings In this cohort study that included 178 healthcare workers, over a 4-month period following the COVID-19 pandemic, participants had an initial rise in anti-nucleocapsid (N) and anti-spike (S) antibodies, which was followed by decay and stabilization of the titres. Significant correlation with rate of decay was noted with the symptomatic participants.Meaning A strong correlation is observed in the decay of anti-S antibody titres based on symptomology, thus eluding to the fact that continued recommendations for infection protection and COVID-19 vaccine campaigns are necessary.Competing Interest StatementF.K. is listed as a co-inventor on a patent application filed by The Icahn School of Medicine at Mount Sinai relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. F.K. has consulted for Merck and Pfizer (before 2020), and is currently consulting for Seqirus and Avimex. F.K.s Krammer laboratory is also collaborating with Pfizer on animal models of SARS-CoV-2.Funding StatementThe authors received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was a cross sectional cohort study done in two phases after receiving Institutional Review Board approval (IRB # 20-009, Lincoln Medical Center, Office of the Institutional Review Board approved as per 45 CFR 46 & 21 CFR50,56 under a full board committee and gave its approval on 4/28/2020).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data that had been collected has been presented in the manuscript.